A detailed history of Israel Englander (Millennium Management LLC) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 239,609 shares of CRDF stock, worth $912,910. This represents 0.0% of its overall portfolio holdings.

Number of Shares
239,609
Previous 683,299 64.93%
Holding current value
$912,910
Previous $3.65 Million 85.44%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.22 - $5.89 $984,991 - $2.61 Million
-443,690 Reduced 64.93%
239,609 $531,000
Q1 2024

May 15, 2024

BUY
$1.46 - $5.91 $997,616 - $4.04 Million
683,299 New
683,299 $3.65 Million
Q2 2023

Aug 14, 2023

SELL
$1.37 - $1.95 $75,628 - $107,645
-55,203 Reduced 53.11%
48,739 $71,000
Q1 2023

May 15, 2023

SELL
$1.45 - $2.09 $53,396 - $76,964
-36,825 Reduced 26.16%
103,942 $172,000
Q4 2022

Feb 14, 2023

SELL
$1.22 - $1.66 $72,004 - $97,973
-59,020 Reduced 29.54%
140,767 $197,000
Q3 2022

Nov 14, 2022

SELL
$1.54 - $3.21 $298,476 - $622,149
-193,816 Reduced 49.24%
199,787 $308,000
Q2 2022

Aug 15, 2022

BUY
$1.17 - $2.61 $127,072 - $283,469
108,609 Added 38.11%
393,603 $866,000
Q1 2022

May 16, 2022

SELL
$2.11 - $7.25 $282,499 - $970,673
-133,886 Reduced 31.96%
284,994 $707,000
Q4 2021

Feb 14, 2022

BUY
$5.18 - $7.24 $1.51 Million - $2.11 Million
291,382 Added 228.54%
418,880 $2.52 Million
Q3 2021

Nov 15, 2021

BUY
$5.01 - $7.58 $638,764 - $966,434
127,498 New
127,498 $849,000
Q2 2021

Aug 16, 2021

SELL
$6.65 - $10.04 $2.15 Million - $3.24 Million
-322,962 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$9.1 - $19.57 $2.65 Million - $5.69 Million
290,921 Added 907.96%
322,962 $2.99 Million
Q4 2020

Feb 16, 2021

SELL
$12.02 - $24.71 $744,182 - $1.53 Million
-61,912 Reduced 65.9%
32,041 $576,000
Q3 2020

Nov 16, 2020

BUY
$4.25 - $14.19 $399,300 - $1.33 Million
93,953 New
93,953 $1.33 Million

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $165M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.